YIH
ARTV

Y-Intercept (HK)’s Artiva Biotherapeutics ARTV Stock Holding History

Y-Intercept (HK)’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-31,567
Closed -$47.7K – 2148
2025
Q2 		$47.7K Buy
+31,567
New +$66.3K ﹤0.01% 1560

Other funds holding ARTV

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Y-Intercept (HK)'s ARTV Position: Q3 2025 in Review

Y-Intercept (HK) sold out of Artiva Biotherapeutics (ARTV) in Q3 2025, closing a stake of 31,567 shares — an estimated $47.7K sold.

Y-Intercept (HK) first reported a position in ARTV in Q2 2025 and held it in 1 quarter. The position peaked at $47.7K in Q2 2025. 40 funds tracked by Wall St. Rank hold ARTV as of Q3 2025.

  • Y-Intercept (HK) reported no remaining Artiva Biotherapeutics position as of Q3 2025 after selling out during the quarter.
  • Y-Intercept (HK) sold 31,567 Artiva Biotherapeutics shares in Q3 2025, an estimated $47.7K.
  • Y-Intercept (HK) first reported a position in Artiva Biotherapeutics in Q2 2025 and held it in 1 quarter.
  • Y-Intercept (HK)'s Artiva Biotherapeutics position peaked at $47.7K in Q2 2025.
  • 40 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q3 2025.

Based on Y-Intercept (HK)'s 13F filing for Q3 2025, filed 31 Oct 2025.